S
237690
vs
K
KOSPI 200
Over the past 12 months, ST Pharm Co Ltd has underperformed KOSPI 200, delivering a return of +10% compared to KOSPI 200's +150% growth.
Stocks Performance
237690 vs KOSPI 200
Performance Gap
237690 vs KOSPI 200
Performance By Year
237690 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ST Pharm Co Ltd
Glance View
ST Pharm Co., Ltd. makes active pharmaceutical ingredients and custom drug ingredients for other drugmakers. Its main work is contract development and manufacturing, especially for oligonucleotide medicines, which are short strands of synthetic DNA or RNA used in newer treatments, as well as certain small-molecule drug ingredients and intermediates. Its customers are pharmaceutical and biotech companies that need a trusted partner to design, develop, and produce these complex ingredients at commercial scale. ST Pharm earns money by charging for development work, custom synthesis, and manufacturing services, rather than by selling branded medicines to patients. What makes the business different is its role deep in the drug supply chain. It does not market finished drugs under its own name; instead, it helps other companies turn early drug ideas into materials that can be used in approved medicines. That makes it a specialist supplier for a technically demanding part of pharmaceutical production.
